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DIALYSIS – TRANSPLANTATION
Risk factors for post-transplant tuberculosis
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Risk factors for post-transplant tuberculosis. Renal transplantation has been increasingly carried
Background. Post-transplant tuberculosis (post-TxTB) oc- out in developing countries. In the Indian subcontinent,
curs in 12 to 20% of patients in India and results in the death an estimated 4000 renal transplantations take place an-of 20 to 25% of those patients. Prospective studies on post-
nually. As reported earlier, infectious complications leadTxTB are few.
Methods. Renal allograft recipients were studied prospec- the causes of morbidity and mortality among these pa-
tively for 3.1 (0 to 13.9) median (range) years for incidence, tients [1]. Powerful immunosuppression prevents organ
manifestations, risk factors, and prognosis for post-TxTB. rejections at the expense of increasing the incidence of
Kaplan-Meier analysis was used to study the survival rates.
ambient and opportunistic infections. It is estimated thatThe extended Cox proportional model for time-dependent co-
in the last decade, at least 50% of the Indian populationvariates was used to measure the risk factors when the hazard
was nonuniform. above the age of 20 years is infected with the tubercle
Results. Of the 1414 patients considered for inclusion, multi- bacillus and remains at risk for the disease [2]. The preva-
ple-transplant subjects (N  37) and patients who developed lence of post-transplant tuberculosis (post-TxTB) in In-pre-transplant TB (pre-TxTB; N  126) were excluded from
dia is reported to be the highest in the world, and thethe study. The prevalence of post-TxTB was 13.3% (N 166).
The risk of post-TxTB when on cyclosporine (CsA) therapy mortality among those afflicted is high at 20 to 25% [3].
was 2.5 (P 0.0311) and 1.9 (P 0.0430) times at6 and12 However, most data on this important disease are from
months, respectively, compared with patients on prednisolone retrospective or short-term studies.plus azathioprine (PRED  AZA). The risk of post-TxTB in
The present report documents the incidence, distribu-the presence of diabetes mellitus, chronic liver disease, and
tion, risk factors, and prognosis of post-TxTB in a largeother co-existing infections [including deep mycoses, cytomeg-
alovirus (CMV), Pneumocystis carinii pneumonia (PCP), no- cohort drawn from all parts of India and surrounding
cardia] was 2.2 (P  0.0011), 1.7 (P  0.0010) and 2.4 (P  countries who were followed up prospectively for over
0.0001) times, respectively. Of the 166 patients with post-TxTB, a decade at a single center.53 patients died, and of those deaths, 17 (32%) were due to
All 1414 patients who received a renal transplantpost-TxTB; 11 (65%) of the 17 had co-existing infections. The
factors associated with death were HLA mismatches, PRED during the study period were studied for the outcome
AZA immunosuppression, pre- and post-TxTB, diabetes melli- analysis. Of this cohort, 126 patients who developed pre-
tus, post-transplant diabetes (PTDM), and other co-existing transplant TB (pre-TxTB) and 37 patients who receivedinfections. The extended Cox model for death as the outcome
multiple transplants and had a different risk profile werevariable showed the following to be significant risk factors:
excluded from the analysis of risk factors for post-TxTB.post-TxTB 2 years (P  0.0036), chronic liver disease 6
years (P  0.0457), PTDM 5 years (P  0.0729), diabetes The mean age of this patient cohort was 32.8  11 (SD)
mellitus (P  0.0091), human lymphocyte antigen match 1 years, and 1033 (82.6%) were males.
antigen (P  0.0134), two to three antigens (P  0.0448), and
the presence of other co-existing infections (P  0.0001).
Conclusions. Cyclosporine therapy is associated with early METHODSpost-TxTB. Diabetes mellitus and chronic liver disease are risk
factors for post-TxTB. The occurrence of both pre-TxTB and Patients
post-TxTB (2 years) along with hyperglycemia, liver disease,
From 1986 to 1999, 1414 patients who received a renaland other co-existing infections are important risk factors for
transplant at the Christian Medical College and Hospitaldeath.
at Vellore in southern India were prospectively studied.
The incidence, distribution, risk factors, and prognosisKey words: renal transplantation, allograft and infection, infection,
tubercle bacillus, bacterial infection, India and TB. of post-TxTB were analyzed. Patients received predniso-
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Table 1. Demographic features, risk factors and outcome oflone plus azathioprine (PRED  AZA) immunosup-
post-transplant tuberculosis (TB)
pression until 1989 and thereafter, PRED  AZA 
Post-TxTB (%) No TB (%)cyclosporine (CsA), or PRED  CsA (CsA at a higher
Variables N166 N1085 P valuedose) was used. CsA was discontinued in most patients
Age years 34.5 (10.3) 32.5 (11.1) 0.0270at one year. Monoclonal antibodies were used for treat-
Follow-up years
ment of recurrent or refractory rejections from 1994. Median, range 1.6 (0.1–11.5) 3.7 (0–13.9) 0.0001
SexMycophenolate mofetil rescue has been used since 1999
Male 138 (83.1) 895 (82.5) 0.7897for CsA toxicity and for recurrent rejections.
Female 28 (16.9) 190 (17.5)
Patients were seen in the center three times weekly Donor age 40.8 (11.7) 40.9 (11.9) 0.9310
Donor sexfor the first two months, twice weekly for the next two
Male 71 (42.8) 496 (45.7) 0.5964months, and once weekly for the fifth and sixth months;
Female 95 (57.2) 589 (54.3)
then they were seen at 9 and 12 months and whenever HLA match
1 26 (15.7) 143 (13.2) 0.4017necessary. The follow-up was 100% at six months, 80%
2–3 116 (69.9) 816 (72.5)at nine months, and 90% at one year. Subsequently, a
4 24 (14.5) 126 (11.6)
clinic follow-up of 40% and communication with another Immunosuppression
PRED  AZA group 61 (36.7) 286 (26.4) 0.139125% of patients with a specific need or on an annual
CsA group 105 (63.3) 799 (73.6)basis was possible.
Chronic liver disease
Patients with pre-TxTB (N  126) had a minimum of Yes 71 (42.8) 251 (23.1) 0.0001
No 95 (57.2) 834 (76.9)six weeks of antituberculosis therapy (ATT) prior to trans-
Hyperglycemiaplantation, completed the course at 18 months, and con-
Diabetes mellitus 19 (11.4) 68 (6.3) 0.0017
tinued lifelong secondary isoniazid chemoprophylaxis. PTDM 27 (16.3) 127 (11.7)
No 120 (72.3) 890 (82.7)Post-TxTB was clinically suspected when a patient pre-
Other co-existing infectionssented with fever or symptoms of organ involvement. In
Yes 30 (18.1) 85 (7.8) 0.0001
some instances, post-TxTB was found on routine physical No 136 (81.9) 1000 (92.2)
Outcomeexamination. Involvement of the lung was studied with
Graft loss 10 (6.0) 88 (8.1) 0.0055radiographs, sputum, gastric juice [4], or bronchoalveolar
Lost to follow-up 16 (9.6) 128 (11.8)
lavage specimens. Tissue diagnosis of affected organ or Renal failure 6 (3.6) 26 (2.4)
Alive 81 (48.8) 630 (58.1)evaluation of exudative effusions was attempted when-
Dead 53 (31.9) 213 (19.6)ever possible these were examined using histopathology,
Abbreviations are: PRED  AZA, prednisolone  azathioprine; PTDM,microscopy, and culture.
post-transplant diabetes mellitus; CsA group, most received cyclosporine immuno-
All patients with post-TxTB were treated with ATT suppression for a year.
for 18 months and were followed up with lifelong, sec-
ondary isoniazid prophylaxis. Until 1990, patients re-
ceived streptomycin for three months, pyrazinamide for
the assumption of proportionality. In the analysis of fac-nine months, and ethambutol isoniazid for 18 months.
tors affecting the outcome, there was a similar violationRifampicin was used in a few patients on PREDAZA,
of proportionality with risk factors for death, namely,doubling the dose of PRED to compensate for cyto-
post-TxTB, chronic liver disease, and post-transplant di-chrome P-450 induction. Since 1994, ofloxacin has been
abetes mellitus (PTDM), defined as fasting blood sugarused for nine months and pyrazinamide for the first three
120 mg/dL and two-hour post-prandial blood sugarmonths along with ethambutol and isoniazid. Primary
200 mg/dL or two elevated levels of either measure-chemoprophylaxis was not used during this period except
ment. These variables were analyzed with extended Coxas part of a trial [5]. Empirical ATT was given when
model for time-dependent covariates using heavy sideradiological evidence suggested TB or for pyrexia of
functions along with the other time-independent vari-unknown origin (PUO) when other tests were negative.
ables that were significant at 20% level of significance
Statistical methods in the univariate Cox regression model [6]. The data
Descriptive statistics, cumulative calendar-year inci- were analyzed using SPSS for Windows software.
dence, and actuarial incidence were calculated for post-
TxTB. Kaplan-Meier analysis and log-rank statistics
RESULTSwere used to study the association between explanatory
Of the remaining 1251 patients, the prevalence of post-variables and post-TxTB.
TxTB was 13.3% (N  166) over a median (range) fol-In analyzing the risk factors for the occurrence of
low-up period of 3.1 (0 to 13.9) years. The patient andtuberculosis and for death, the variables were checked
donor characteristics, risk factors, and outcome are shownfor proportionality assumptions. In the analysis of the
occurrence of post-TxTB, immunosuppression violated in Table 1. The distribution of liver disease, diabetes melli-
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Fig. 1. (A) Calendar-year incidence ( ) and three-year moving aver-
age (MA; ) of post-transplantation tuberculosis (post-TxTB). (B)
Overall actuarial incidence  1 SE of post-TxTB. (C ) Kaplan-Meier
graph for survival without post-TxTB in patients treated with (thin line)
and without (thick line) cyclosporine A (CsA).
Table 2. Manifestations of post-transplant tuberculosis.tus, other co-existing infections [deep mycoses, cytomeg-
alovirus (CMV), Pneumocystis carinii pneumonia (PCP), TB location (N166) N (%)
nocardia] and the distribution of death was significantly Lung and pleura 80 (48.2)
Disseminated 32 (19.3)more in patients with post-TxTB (31.9%) as compared
Pyrexia of unknown origin 26 (15.7)with those without the disease (19.6%, P  0.0055).
Lymph node 8 (4.8)
However, the distribution of graft loss or renal failure Skin and soft tissue 7 (4.2)
Intestine 5 (3.0)(creatinine 3.5 mg/dL) was similar in both groups.
Central nervous system 3 (1.8)The calendar-year incidence of post-TxTB in renal
Bone 2 (1.2)
transplant recipients was computed per 100 patients and Pericardial 2 (1.2)
Urinary tract 1 (0.6)is shown in Figure 1A. There was a year-to-year variation,
and the three-year moving average indicates a lower inci-
dence during the latter half of the study period as com-
pared with 1980s and early 1990s. There is a declining
incidence of post-TxTB with the passing years after trans- (25.9%) patients of whom 26 had a PUO that responded to
treatment. The remaining 17 had exudative, lymphocyticplantation (Fig. 1B).
The distribution of lesions of post-TxTB is shown in effusions, or radiological lesions highly suggestive of TB.
In two patients, the diagnosis of post-TxTB was possibleTable 2. Pleuropulmonary involvement was seen in 48.2%
and disseminated tuberculosis in 19.3% of patients. Three only with post-mortem examination. The probability of
patients surviving without post-TxTB was 93.5, 86, andfourths of patients had histopathological or microbiolog-
ical proof of tuberculosis. Empirical ATT was given to 43 82.6% on CsA immunosuppression and 95.6, 83.4, and
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Table 4. Distribution of demographic details for patientsTable 3. Risk factors for post-TxTB.
dead and alive
Variables HR 95% CI P value
Dead (%) Alive (%)
Age 1.01 1.00–1.03 0.0500 Variables N318 N1096 P value
Hyperglycemia
Diabetes mellitus 2.24 1.38–3.65 0.0011 Age 35.9 (12.4) 32.1 (10.31) 0.0001
Follow-up yearsPTDM 1.12 0.73–1.70 0.6094
No 1.00 Median, range 1.5 (0–11.9) 4.0 (0–13.9) 0.0001
SexChronic liver disease
Yes 1.72 1.24–2.39 0.0010 Male 253 (79.6) 916 (83.6) 0.1132
Female 65 (20.4) 180 (16.4)No 1.00
Other co-existing infections Donor age 40.2 (12.2) 40.7 (11.9) 0.4390
Donor sexYes 2.35 1.57–3.54 0.0001
No 1.00 Male 154 (48.4) 507 (46.3) 0.4893
Female 164 (51.6) 589 (53.7)Immunosuppression (TDC)
Cyclosporine 6 months 2.45 1.08–5.54 0.0311 HLA match
1 63 (19.8) 151 (13.8) 0.0480Cyclosporine 6 months 0.76 0.52–1.11 0.1539
PRED  AZA 1.00 2–3 222 (69.8) 809 (73.8)
4 33 (10.4) 136 (12.4)Immunosuppression (TDC)
CsA group 0-12 months 1.85 1.02–3.37 0.0430 Immunosuppression
PRED  AZA 138 (43.4) 262 (23.9) 0.0001CsA group 12 months 0.68 0.45–1.03 0.0693
PRED  AZA 1.00 CsA group 180 (56.6) 834 (76.1)
TBAbbreviations are: PRED  AZA, prednisolone  azathioprine; PTDM,
Pre-transplant TB 32 (10.1) 88 (8.0) 0.0091post-transplant diabetes mellitus; TDC, time-dependent covariate; CsA group,
Post-transplant TB 59 (18.6) 116 (10.6)most received cyclosporine immunosuppression for a year.
No 227 (71.4) 892 (81.4)Adjusted hazard ratio (HR), 95% confidence interval (CI) and P value (time-
dependent covariate) are shown. Chronic liver disease
Yes 106 (33.3) 274 (25.0) 0.2343
No 212 (66.7) 822 (75.0)
Hyperglycemia
Diabetes mellitus 43 (13.5) 59 (5.4) 0.0001
75% on PREDAZA at 1, 5 and 10 years, respectively PTDM 43 (13.5) 131 (12.0)
No 232 (73.0) 906 (82.7)(Fig. 1C).
Other co-existing infectionsOn examination of the associations of the risk factors
Yes 63 (19.8) 70 (6.4) 0.0001
for post-TxTB using univariate analysis, age [hazard ra- No 255 (80.2) 1026 (93.6)
tio (HR), 1.02; 95% CI, 1.01 to 1.04, P 0.0015], chronic Alive includes lost to follow-up, patients with graft loss and renal failure.
Abbreviations are: PRED  AZA, prednisolone  azathioprine; PTDM, post-liver disease (HR, 1.96; 95% CI, 1.44 to 2.67, P 0.0001),
transplant diabetes mellitus; CsA group, most received cyclosporine immunosup-diabetes mellitus (HR, 2.31; 95% CI, 1.42 to 3.76, P  pression for a year.
0.0007), PTDM (HR, 1.31; 95% CI, 0.86 to 1.99, P 
0.2025), other co-existing infections (deep mycoses, CMV,
PCP, nocardia; HR, 2.74; 95% CI, 1.84 to 4.06, P 0.0001)
and CsA immunosuppression 0 to 12 months (HR, 1.49;
The distribution of risk factors and demographic de-95% CI, 0.83 to 2.69, P  0.1839) were found to be
tails of patients who died and of others are detailed insignificant. Further multivariate modeling with these
Table 4. The probability of survival with pre-TxTB wasvariables demonstrated that the risk of post-TxTB in the
86.7, 66.7, and 66.7% and with post-TxTB was 92.5, 68.3,presence of diabetes mellitus and chronic liver disease
and 52.5% at 1, 5, and 10 years, respectively. In compari-was 2.2- and 1.7-fold, respectively. The relative risk of
son, the survival in patients without TB was 91.1, 76.7,other co-existing infections (deep mycoses, CMV, PCP,
and 70.8%, respectively (P  0.0091). On univariatenocardia) was 2.4 times in the presence of post-TxTB.
analysis, the factors associated with death were the recip-The risk of post-TxTB on CsA was 2.5 times at6 months
ient age (HR, 1.03; 95% CI, 1.02 to 1.04, P  0.0001),and 1.9 times at 0 to 12 months when compared with
HLA 1 antigen match (HR, 1.62; 95% CI, 1.06 to 2.47,patients on PRED  AZA. However, the risk for post-
P  0.0236), PRED  AZA immunosuppression (HR,TxTB 12 months on PRED  AZA was 1.5 times as
1.66; 95% CI, 1.32 to 2.08, P  0.0001), pre-TxTB (HR,compared with those who had received CsA immunosup-
1.37, 95% CI, 0.94 to 1.98, P  0.0925), post-TxTB 2pression (Table 3).
years (HR, 2.25; 95% CI, 1.50 to 3.37, P  0.0001),The outcome of patients with post-TxTB was studied
chronic liver disease 6 years (HR, 3.33; 95% CI, 1.43in comparison with those who did not develop the disease.
to 7.73, P  0.0051), diabetes mellitus (HR, 2.50; 95%Of the 166 patients who developed post-TxTB, 53 pa-
CI, 1.80 to 3.46, P 0.0001), PTDM5 years (HR, 2.35;tients died and of these deaths, 17 (32%) were from
95% CI, 1.17 to 4.73, P  0.0165), and the presence ofpost-TxTB. An associated co-existence of other infec-
other co-existing infections (HR, 2.91; 95% CI, 2.21 totions (deep mycoses, CMV, PCP, nocardia, and hepato-
3.84, P  0.0001). Analyzing these time-dependent vari-tropic viral infections with chronic liver disease) contrib-
uted to the deaths of 11 (65%) of these 17 patients. ables using the extended Cox model for death as the
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Table 5. Risk factors for death using the extended Cox model The early occurrence of post-TxTB in these patients
on CsA has been suggested before [10] and is demon-Variables HR 95% CI P value
strated in this large cohort. This occurs due to CsA therapyAge 1.03 1.02–1.04 0.0001
Sex depressing the lymphocyte proliferation and macro-
Male 0.74 0.56–0.98 0.0341 phage function by down-regulating the release of inter-
Female 1.00
leukin-2 and tumor necrosis factor- [11]. Most patientsHLA match
1 1.71 1.12–2.61 0.0134 on CsA who are likely to develop post-TxTB will have
2–3 1.48 1.02–2.14 0.0448 developed the disease by six years. After six years, post-
4 1.00
TxTB rarely occurs in CsA-treated patients unless thereImmunosuppression
PRED  AZA 1.62 1.27–2.07 0.0001 is an unusually heavy environmental exposure. This pat-
CsA group 1.00 tern suggests a process of reactivation of dormant foci
Other co-existing infections
of TB. Lymph nodal disease occurs only in a minority,Yes 2.91 2.18–3.87 0.0001
No 1.00 as the disease escapes beyond the confines of the reticu-
TB loendothelial system in the immunosuppressed patient.
Pre-transplant TB 1.31 0.90–1.90 0.1573
The risks associated with the development of post-Post-TxTB 2 years 0.82 0.54–1.25 0.3649
Post-TxTB 2 years 1.84 1.22–2.78 0.0036 TxTB have so far not been studied systematically. This
No 1.00 study with the largest number of affected individuals
Chronic liver disease
reported so far shows that diabetes mellitus and chronicLiver 6 years 0.79
Liver 6 years 2.39 0.61–1.04 0.0987 liver disease independently increase the risk of devel-
No 1.00 1.02–5.62 0.0457 oping post-TxTB 1.7 times. The presence of other co-
Hyperglycemia
existing infections (deep mycoses, CMV, PCP, nocardia)Diabetes mellitus 1.66 1.13–2.42 0.0091
PTDM 5 years 0.67 0.46–0.99 0.0454 is an important association. These features mark the
PTDM 5 years 1.91 0.94–3.89 0.0729 individual at risk who, when clinically suspect, warrants
No 1.00
more detailed investigations.
Abbreviations are: HR, adjusted hazard ratio; PREDAZA, prednisolone The risk of death has been approximately 20 to 25%azathioprine; PTDM, post-transplant diabetes mellitus; Post-TxTB, post-trans-
plant tuberculosis; CsA group, most received cyclosporine immunosuppression in a detailed literature review [7] and in a report from
for a year. India [3]. The death rate depends on the study duration
of the cohort following transplantation. Later post-trans-
plant years witness a smaller number of cases of TB but
outcome variable, the significant risk factors were post-
higher death rates. Post-TxTB occurring after two years
TxTB 2 years, chronic liver disease 6 years, diabetes
of transplantation independently carries a 1.8-fold risk
mellitus, PTDM 5 years, HLA mismatches, and pres-
of death as compared with patients who did not develop
ence of other co-existing infections (Table 5).
the disease. Post-TxTB that occurs away from medical
observation beyond two years is again undetected until
DISCUSSION the patient is often moribund. In contrast, post-TxTB
occurring within the first two years does not increaseThe prevalence of post-TxTB in the developed West-
risk of death.ern nations ranges from 1 to 4% [7, 8], while reports from
Tuberculosis occurring two years after transplantationIndia show a much higher prevalence. This remarkable
as well as pre-transplant TB are risk factors for deathdifference in prevalence is a result of high endemic TB
after the transplant, as are diabetes mellitus, PTDM,in India. There is a variation in prevalence within the
chronic liver disease, and the occurrence of other coexist-country, as 11.8% were found in northern India [3],
ing infections such as deep mycoses, CMV, PCP, and13.3% in the southern area (present study), and 8.3%
nocardia. The hazard of death with chronic liver diseasein a previous report [9]. This is in part a result of the
and post-transplant DM varies with time. Chronic livervarying proportion of patients receiving empirical ther-
disease independently increases the risk of death three-apy; for example, empirical therapy was reported in 39%
fold at six years after transplantation. Unabated viralof post-TxTB patients [3], while in the present study,
proliferation, hepatic fibrosis, and subsequent liver dys-26% patients received empirical therapy. The duration
function take approximately six years to manifest in ourof TB after transplantation in our cohort altered the
population. Post-transplant DM that occurs five yearsprevalence of post-TxTB, because the disease incidence
after transplantation doubles the risk of death. This isdeclines in the late post-transplant years.
related to a period of unrecognized hyperglycemia oc-The calendar-year incidence of post-TxTB is impor-
curring in some patients, which results in a higher suscep-tant baseline data for practitioners of transplant medi-
tibility and poor response to infections.cine in developing countries to help the early detection
These observations are unique to vast developing coun-of an unusually high incidence of post-TxTB, occurring
due to unusual exposure or risk factors. tries such as India where appropriate medical care is not
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